

Form PTO-449

U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
P51160SERIAL NO.
09/912,483**INFORMATION DISCLOSURE STATEMENT BY
APPLICANT***(Use several sheets if necessary)*APPLICANT
Erskine, et al.FILING DATE
July 25, 2001GROUP
1614**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
QAT	AA	3,133,061	05-1964	Kirchner, F. K.			
	AB	4,108,998	08-1978	Demerson, et al.			
	AC	5,426,224	06-1995	Lee, et al.			
	AD	6,063,801	05-2000	LaVoie, et al.			
	AE	6,174,678	01-2001	Menzei, et al.			
	AF	SN 09/912,610	07-2001	Erskine, et al.			
	AG	SN 10/199,933	07-2002	Erskine, et al.			
	AF	SN 60/391,700	26 June 2002	Axten, et al.			
QAT	AG	SN 60/391,710	26 June 2002	Axten, et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
QAT	BA	WO/0043383	17 Jan 2000	PCT				
	BB	WO/0078748	13 June 2000	PCT				
	BC	WO/0208224	25 July 2001	PCT				
	BD	WO/107432	17 July 2000	PCT				
	BE	WO/107433	17 July 2000	PCT				
	BF	WO/224684	19 Sept 2001	PCT				
	BG	WO/0250040	19 Dec 2001	PCT				
	BH	WO/0256882	22 Jan. 2002	PCT				
	BI	WO/02/096907	25 May 2001	PCT				
	BJ	WO/02/096907	25 May 2001	PCT				
	BK	PCT/EP02/05708	25 May 2001	PCT				
	BL	WO/03/010138	26 July 2001	PCT				
	BM	PCT/EP03/00824	29 Jan. 2002	PCT				
QAT	BN	PCT/EP03/00823	29 Jan 2002	PCT				

RECEIVED**JUN 17 2003****OFFICE OF PETITIONS****OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

QAT	CA	Le Bras et al. "La Détermination de la Chimosensibilité de Plasmodium Falciparum" (1987) Annales de Pédiatrie, 34(5), 349-356.
QAT	CB	Girault et al., "Antimalarial, Antitrypanosomal, and Antileishmanial Activities and Cytotoxicity of Bis (9-amino-6-chloro-2-methoxyacridines): Influence of the Linker" (2000) J. Med. Chem., 43(14), 2646-2654.

EXAMINER

James Blum

DATE CONSIDERED

7/17/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DEC 03 2001

Sheet 1 of 2

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
P51113SERIAL NO.
09/912,610INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Erskine, et al.FILING DATE
July 25, 2001GROUP
~~Unknown~~ 1657

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
JW	AA	WO 00/21952	20.04.00	PCT				
JW	AB	WO 99/37635	29.07.99	PCT				
JW	AC	WO 00/21948	20.04.00	PCT				

RECEIVED


JUN 17 2003

OFFICE OF PETITIONS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JW	AD	Couturier, et al., "Bacterial death by DNA gyrase poisoning", <i>Trends in Microbiology</i> , 6(7): 269-275 (1998).
JW	AE	Y. Pommier, "Diversity of DNA topoisomerases I and inhibitors", <i>Biochimie</i> , 80: 255-270 (1998).
JW	AF	Smith, et al., "Quinazoline Derivatives. II. Synthesis of 4-(4'-Diethylamino-1'-methylbutyl-amino)-6-methoxyquinazoline (SN 12,253)", <i>Journal of American Chemical Society</i> , 68: 1301-1303 (1946).
JW	AG	R.B. Merrifield, "Solid Phase Peptide Synthesis. I. the Synthesis of a Tetrapeptide", <i>Journal of American Chemical Society</i> , 85: 2149-2154 (1963).
JW	AH	Neil Osheroff, "Eukaryotic Topoisomerase II Characterization of Enzyme Turnover", <i>The Journal of Biological Chemistry</i> , 261(21): 9944-9950 (1985).
JW	AI	Drlica, et al., "DNA Gyrase, Topoisomerase IV, and the 4-Quinolones", <i>Microbiology and Molecular Biology Reviews</i> , 61(3): 377-392 (1997).
JW	AJ	Neil Osheroff, "Biochemical Basis for the Interactions of Type I and Type II Topoisomerases with DNA", <i>Pharmacology & Therapeutics</i> , 41: 223-241 (1989).
JW	AK	D'Incalci, et al., "DNA-topoisomerase inhibitors", <i>Current Opinions in Oncology</i> , 5: 1023-1028 (1993).
JW	AL	Capranico, et al., "DNA sequence selectivity of topoisomerases and topoisomerase poisons", <i>Biochimica et Biophysica Acta</i> , 1400: 185-194 (1998).
JW	AM	Wessel, et al., "Human Small Cell Lung Cancer NYH Cells Selected for Resistance to the Bisdioxopiperazine Topoisomerase II Catalytic Inhibitor ICRF-187 Demonstrate a Functional R162Q Mutation in the Walker A Consensus ATP Binding Domain of the α Isoform", <i>Cancer Research</i> , 59: 3442-3450 (1999).
JW	AN	Hiasa, et al., "Topoisomerase IV Can Support <i>oriC</i> DNA Replication in Vitro", <i>The Journal of Biological Chemistry</i> , 269(23): 16371-16375 (1994).


09 Apr 03



Sheet 2 of 2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. P51113	SERIAL NO. 09/912,610
	APPLICANT Erskine, <i>et al.</i>	
	FILING DATE July 25, 2001	GROUP Unknown 1651

AO	Fortune, <i>et al.</i> , "Merbarone Inhibits the Catalytic Activity of Human Topoisomerase II α by Blocking DNA Cleavage", <i>The Journal of Biological Chemistry</i> , 273(28): 17643-17650 (1998).
AP	Chini, <i>et al.</i> , "Regioalternating Selectivity in the Metal Salt Catalyzed Anionolysis of Styrene Oxide", <i>Journal of Organic Chemistry</i> , 56: 5939 - 5942 (1991).
AQ	Anthony Maxwell, "Protein gates in DNA topoisomerase II", <i>Nature Structural Biology</i> , 3(2): 109-112 (1996).
AR	Nishibata, <i>et al.</i> , "Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation.", <i>Tetrahedron</i> , 47(43): 8985-8990 (1991).
AS	Olland, <i>et al.</i> , "Catalysis of ATP Hydrolysis by Two NH ₂ -terminal Fragments of Yeast DNA Topoisomerase II", <i>The Journal of Biological Chemistry</i> , 274(31): 21688 - 21694 (1999).
AT	Roca, <i>et al.</i> , "Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp", <i>Proceedings of the National Academy of Sciences USA</i> , 91: 1781 - 1785 (1994).
AU	Stingl, <i>et al.</i> , "Process for the preparation of 2-(S)-piperazinecarboxylic acid by continuous resolution via diastereomeric salt pairs", <i>Tetrahedron: Asymmetry</i> , 8(7): 979-982 (1997).
AV	Anthony Maxwell, "DNA gyrase as a drug target", <i>Trends in Microbiology</i> , 5(3): 102 - 109 (1997).
AW	Critchlow, <i>et al.</i> , "DNA Cleavage Is Not Required for the Binding of Quinolone Drugs to the DNA Gyrase-DNA Complex", <i>Biochemistry</i> , 35: 7387 - 7393 (1996).
AX	Capranico, <i>et al.</i> , "DNA topoisomerase II poisons and inhibitors", <i>Cancer Chemotherapy and Biological Response Modifiers Annual 17</i> , Elsevier Science, Chapter 6, pp. 114-131 (1997).

EXAMINER 	DATE CONSIDERED 09 Apr 03
---	------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

N:\ERG\APPS\VP51160\1449.doc

RECEIVED

JUN 17 2003

OFFICE OF PETITIONS